-- Global Action Follows Notification of Updated Safety Information from the?U.S. Food and Drug Administration?(FDA) --? -- FDA Does Not Recommend Removal or Replacement of Textured Breast Implants in Asymptomatic Patients -- --?Smooth and MICROCELL??Breast Implants and Tissue Expanders Not Impacted -- DUBLIN,?July 24, 2019?/PRNewswire/ --?Allergan plc?(NYSE: AGN) today announced a voluntary worldwide recall of BIOCELL^??textured breast implants and tissue expanders.?Allergan?is taking this action as a precaution following notification of recently updated global safety information concerning the uncommon incidence of?breast implant-associated?anaplastic large cell lymphoma (BIA-ALCL) provided by the U.S. Food and Drug Administration?(FDA). BIOCELL^??saline-filled and silicone-filled textured breast implants and tissue expanders will no longer be distributed or sold in any market where they are currently available. Effective immediately, healthcare providers should no longer implant new BIOCELL^??textured breast implants and tissue expanders and unused products should be returned to?Allergan.?Allergan?will provide additional information to customers about how to return unused products. Patient safety is a priority for?Allergan. Patients are advised to speak with their plastic surgeon about the risks and benefits of their implant type should they have any concerns. Importantly, the?FDA?and other health authorities have not recommended removal or replacement of textured breast implants?or tissue expanders?in asymptomatic patients. This global recall does not affect?Allergan's?NATRELLE^??smooth or MICROCELL^??breast implants and tissue expanders. The recalled products include: U.S. healthcare providers with questions regarding this announcement can contact Medical Information at 1-800-678-1605 option #2 or?IR-Medcom@allergan.com. For all other countries, please use the contact details at the following link on?Allergan's?website:?Allergan Global Medical Information Contacts. Adverse events or quality problems experienced with the use of this product may be reported to the?FDA's?MedWatch Adverse Event Reporting Program either online, by regular mail or by fax.

• Complete and submit the report Online:?www.fda.gov/medwatch/report.htm
• Regular Mail or Fax: download form?www.fda.gov/MedWatch/getforms.htm?or call 1-800-FDA-1088 to request form, then complete and return address on the pre-addressed form, or submit by fax to 1-800-FDA-0178.

About?Allergan?plc?? Allergan plc?(NYSE: AGN), headquartered in?Dublin, Ireland, is a global pharmaceutical leader focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world.?Allergan?markets a portfolio of leading brands and best-in-class products primarily focused on four key therapeutic areas including medical aesthetics, eye care, central nervous system and gastroenterology. As part of its approach to delivering innovation for better patient care,?Allergan?has built one of the broadest pharmaceutical and device research and development pipelines in the industry. With colleagues and commercial operations located in approximately 100 countries,?Allergan?is committed to working with physicians, healthcare providers and patients to deliver innovative and meaningful treatments that help people around the world live longer, healthier lives every day. For more information, visit?Allergan's?website at?www.Allergan.com. Forward-Looking Statement? Statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect?Allergan's?current perspective on existing trends and information as of the date of this release. Actual results may differ materially from?Allergan's?current expectations depending upon a number of factors affecting?Allergan's?business. These factors include, among others, the difficulty of predicting the timing or outcome of?FDA?approvals or actions, if any; the impact of competitive products and pricing; market acceptance of and continued demand for?Allergan'sproducts; the impact of uncertainty around timing of generic entry related to key products, including RESTASIS^?, on our financial results; risks associated with divestitures, acquisitions, mergers and joint ventures; risks related to impairments; uncertainty associated with financial projections, projected cost reductions, projected debt reduction, projected synergies, restructurings, increased costs, and adverse tax consequences;?difficulties or delays in manufacturing; and other risks and uncertainties detailed in?Allergan's?periodic public filings with the?Securities and Exchange Commission, including but not limited to?Allergan's?Annual Report on Form 10-K for the year ended?December 31, 2018?and?Allergan'sQuarterly Report on Form 10-Q for the period ended?March 31, 2019. Except as expressly required by law,?Allergan?disclaims any intent or obligation to update these forward-looking statements. CONTACTS:?????? Allergan: Investors:? Manisha Narasimhan, PhD (862) 261-7162 Christine Chiou (862) 261-7396 Media: Fran DeSena (862) 261 8820 Mark Marmur +44 7725 758677 Lisa Brown (862) 261-7320